Bladder Carcinoma, Transitional Cell Carcinoma, Urothelial Carcinoma
Conditions
Brief summary
The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.
Detailed description
OUTLINE: This is a multi-center study Patients will be enrolled into one of two parallel cohorts: * Cohort 1: impaired renal function AND poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily * Cohort 2: impaired renal function OR poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 on D1, 8, 15 Restaging evaluations will be performed after every 2 cycles. Treatment will continue until disease progression or unacceptable toxicity. Karnofsky performance status 60-70% Life Expectancy: Not specified Hematopoietic: * Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 * Hemoglobin (Hgb) ≥ 9 g/dL * Platelets ≥ 100 K/mm3 * INR ≤ 1.5 (Anticoagulants are allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of Low molecular weight (LMW) heparin for at least 2 weeks prior to registration for protocol therapy). * Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L * Fasting triglycerides ≤ 2.5 x ULN. * Fasting serum glucose \< 1.5 x ULN Hepatic: * Bilirubin ≤ 1.5 x ULN * Aminotransferases (AST and ALT) ≤ 2.5 x ULN (unless liver metastases, then ≤ 5 x ULN) Renal: * Calculated creatinine clearance of \< 60 using the Cockcroft-Gault formula Cardiovascular: * No symptomatic congestive heart failure of New York heart Association Class III or IV. * No unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
Interventions
DRUGEverolimus
10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
DRUGPaclitaxel
Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
Sponsors
Hoosier Cancer Research Network
Novartis Pharmaceuticals
Matthew Galsky
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC. * Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy. * Must be ineligible for cisplatin, based on the following, within 30 days prior to registration for protocol therapy. * Prior radiation therapy is allowed to \< 25% of the bone marrow. * Written informed consent and HIPAA authorization for release of personal health information. * Age \> 18 years at the time of consent. * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to prior to registration for protocol therapy. * Females must not be breastfeeding.
Exclusion criteria
* No prior chemotherapy for metastatic disease. Prior chemotherapy in the neoadjuvant/adjuvant setting is allowed if completed at least 12 months prior to registration for protocol therapy. * No active CNS metastases or leptomeningeal metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis. * No prior malignancy is allowed except for adequately treated basal cell or adequately treated squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers (treated definitively with no evidence of PSA progression), or other cancer for which the patient has been disease-free for at least 5 years. * No treatment with any anticancer therapy or investigational agent within 30 days prior to registration for protocol therapy. * No known hypersensitivity to any protocol treatment. * No prior treatment with mTOR inhibitor (sirolimus, temsirolimus, everolimus). * No history of immunization with attenuated live vaccines within one week prior to registration for protocol therapy or during study period. * No severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air. * No uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN. * No active (acute or chronic) or uncontrolled severe infections. * No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis. * No known history of HIV seropositivity. * No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). * No active, bleeding diathesis. * No history of major surgery (defined as requiring general anesthesia) or significant traumatic injury within 30 days prior to registration for protocol therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel | 4 months | To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events as a Measure of Safety and Tolerability | 5 months | To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided. |
| Progression Free Survival | 4 months | To determine median progression free survival per RECIST 1.1, per cohort. |
| Overall Survival | 12 months | To determine median overall survival at 1-year from the initiation of treatment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Everolimus Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)
Everolimus: 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis. | 7 |
| Everolimus Plus Paclitaxel Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)
Everolimus: 10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
Paclitaxel: Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle. | 29 |
| Total | 36 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 9 |
| Overall Study | Death | 0 | 2 |
| Overall Study | Disease Progression | 3 | 14 |
| Overall Study | Symptomatic Deterioration | 1 | 1 |
| Overall Study | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Everolimus | Total | Everolimus Plus Paclitaxel |
|---|---|---|---|
| Age, Continuous | 78 years | 73.28 years | 72.14 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 35 Participants | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Karnovsky Performance Status (KPS) at Screening KPS 100 | 0 Participants | 4 Participants | 4 Participants |
| Karnovsky Performance Status (KPS) at Screening KPS 60 | 6 Participants | 9 Participants | 3 Participants |
| Karnovsky Performance Status (KPS) at Screening KPS 70 | 1 Participants | 5 Participants | 4 Participants |
| Karnovsky Performance Status (KPS) at Screening KPS 80 | 0 Participants | 12 Participants | 12 Participants |
| Karnovsky Performance Status (KPS) at Screening KPS 90 | 0 Participants | 6 Participants | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 5 Participants | 32 Participants | 27 Participants |
| Region of Enrollment United States | 7 participants | 36 participants | 29 participants |
| Sex: Female, Male Female | 2 Participants | 9 Participants | 7 Participants |
| Sex: Female, Male Male | 5 Participants | 27 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 7 / 7 | 25 / 29 |
| other Total, other adverse events | 5 / 7 | 28 / 29 |
| serious Total, serious adverse events | 1 / 7 | 11 / 29 |
Outcome results
Primary
Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel
To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1 | Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel | 14.3 percentage of participants |
| Cohort 2 | Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel | 37.9 percentage of participants |
Secondary
Number of Adverse Events as a Measure of Safety and Tolerability
To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.
Time frame: 5 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 2 Adverse Events | 9 Number of Events |
| Cohort 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 4 Adverse Events | 0 Number of Events |
| Cohort 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 3 Adverse Events | 4 Number of Events |
| Cohort 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 5 Adverse Events | 0 Number of Events |
| Cohort 1 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 1 Adverse Events | 10 Number of Events |
| Cohort 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 5 Adverse Events | 3 Number of Events |
| Cohort 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 1 Adverse Events | 116 Number of Events |
| Cohort 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 2 Adverse Events | 75 Number of Events |
| Cohort 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 3 Adverse Events | 39 Number of Events |
| Cohort 2 | Number of Adverse Events as a Measure of Safety and Tolerability | Grade 4 Adverse Events | 1 Number of Events |
Secondary
Overall Survival
To determine median overall survival at 1-year from the initiation of treatment.
Time frame: 12 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 | Overall Survival | 4.5010 months |
| Cohort 2 | Overall Survival | 10.8747 months |
Secondary
Progression Free Survival
To determine median progression free survival per RECIST 1.1, per cohort.
Time frame: 4 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 | Progression Free Survival | 2.3327 months |
| Cohort 2 | Progression Free Survival | 5.8480 months |